Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
2.090
0.00 (0.01%)
Mar 31, 2025, 10:55 AM EDT - Market open

Aprea Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
1.50.58---
Revenue Growth (YoY)
157.63%----
Cost of Revenue
9.367.6316.423.9-
Gross Profit
-7.86-7.04-16.4-23.9-
Selling, General & Admin
6.468.4320.9713.5514.93
Research & Development
----37.88
Operating Expenses
6.468.4320.9713.5552.81
Operating Income
-14.32-15.47-37.37-37.45-52.81
Interest & Investment Income
1.291.220.4500.22
Currency Exchange Gain (Loss)
0.07-0.040.280.32-0.89
EBT Excluding Unusual Items
-12.96-14.29-36.64-37.13-53.48
Pretax Income
-12.96-14.29-112.66-37.13-53.48
Net Income
-12.96-14.29-112.66-37.13-53.48
Net Income to Common
-12.96-14.29-112.66-37.13-53.48
Shares Outstanding (Basic)
64211
Shares Outstanding (Diluted)
64211
Shares Change (YoY)
52.31%118.31%55.69%0.72%-
EPS (Basic)
-2.35-3.95-67.99-34.88-50.61
EPS (Diluted)
-2.35-3.95-67.99-34.88-50.61
Free Cash Flow
-13.57-12.27-25.01-37.69-41.83
Free Cash Flow Per Share
-2.46-3.39-15.09-35.41-39.59
Operating Margin
-953.00%-2652.80%---
Profit Margin
-862.43%-2449.59%---
Free Cash Flow Margin
-903.26%-2103.92%---
EBITDA
-14.3-15.46-37.37-37.43-52.78
D&A For EBITDA
0.020.0100.010.03
EBIT
-14.32-15.47-37.37-37.45-52.81
Updated Mar 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q